UnknownPHASE1, PHASE2NCT06224842
Clinical Study of Mitoxantrone Liposome and Azacitidine in the Treatment of R/R AITL
Studying Angioimmunoblastic T-cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Huijing Wu
- Principal Investigator
- Huijing WuHubei Cancer Hospital
- Intervention
- mitoxantrone liposome 16 and azacitidine(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2023 – 2025
Study locations (1)
- Hubei Cancer Hospital, Wuhan, Hubei, China
Collaborators
Beijing Xisike Clinical Oncology Research Foundation · CSPC-NBP Pharmaceutical Co., Ltd.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06224842 on ClinicalTrials.govOther trials for Angioimmunoblastic T-cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07168317Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of New Diagnosed AITLThe Affiliated Hospital of Xuzhou Medical University
- RECRUITINGPHASE3NCT06522737A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) PhenotypeSecuraBio
- RECRUITINGPHASE2NCT07058103Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of R/R AITLThe Affiliated Hospital of Xuzhou Medical University
- RECRUITINGPHASE2NCT06756308A Study of Enasidenib in People With T-Cell LymphomaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1NCT06393738A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.Arvinas Inc.
- ACTIVE NOT RECRUITINGPHASE4NCT07046182Clinical Study of CEP+Dasatinib + Azacytidine in First-line Treatment of. Angioimmunoblastoma ForesightZhengzhou University
- ACTIVE NOT RECRUITINGPHASE3NCT03703375Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell LymphomaCelgene